The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > REGULATORY
REGULATORY
- Japan to Research Duration of COVID-19 Vaccine Efficacy: Minister
March 31, 2021
- Label Revisions Ordered for Utemerin and More Drugs, 1st Update for Zolgensma
March 31, 2021
- 1.35% of Tokyo Residents Have Coronavirus Antibodies: MHLW
March 31, 2021
- Govt’s Drug Development Panel Adopts 5 Priority Topics for Discussion
March 31, 2021
- Govt to Set Up Taskforce to Spur Development of Japan-Made Vaccines
March 30, 2021
- Japan Gives Up on Setting New Generic Target by March as Manufacturing Scandals Weigh
March 30, 2021
- LDP League Submits Request to Reinstate HPV Vaccine Promotion
March 30, 2021
- MHLW Panel Approves List of “Stable Supply Medicines”; Pricing to Become Topic of Discussions
March 30, 2021
- Japan to Wade Deeper into Generic Industry Revamp in New Pharma Vision, Due Out Summer
March 29, 2021
- Govt Plans Switch to 6-Dose Syringes for Elderly “Sometime in May”: Kono
March 29, 2021
- 35.6% of Pfizer Vaccine Recipients Developed Fevers after 2nd Shot, Higher Incidence in Women: MHLW
March 29, 2021
- Nichi-Iko Starting Marketing Operations from March 29
March 29, 2021
- LDP Group to Submit Request for HPV Vaccine Promotion Resumption
March 26, 2021
- Chuikyo to Compile Reimbursement Rule for Therapeutic Apps by Year-End
March 25, 2021
- Chuikyo Members Rail against Generic Manufacturing Scandals
March 25, 2021
- Chuikyo OKs Appraisal Results for Kymriah, Trelegy; Downward Price Tweaks Expected
March 25, 2021
- 6.1% of Hospitals Have Established Formularies: Chuikyo Survey
March 25, 2021
- Nichi-Iko Plant Probed before Lifting of Biz Suspension Order
March 25, 2021
- MHLW Notifies of Guidelines on Use of Registry Data in Regulatory Submissions
March 25, 2021
- Toyama Govt to Probe Repeated Failures to Discover Nichi-Iko’s GMP Violations
March 25, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…